EXOZ — EXOZYMES INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2010788 ·
Last close
$4.65
Market Cap
$43.16M
52W High
$11.30
52W Low
$4.35
ADV30
12,733
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,386,974 | -2,370,247 | 4,018,841 | 1,444,562 | 2,490,741 |
| Dec 2025 | 0 | — | -2,695,490 | -2,655,036 | 5,971,517 | 3,039,343 | 2,574,268 |
| Sep 2025 | 0 | — | -2,522,208 | -2,286,991 | 7,719,049 | 5,098,687 | 2,344,627 |
| Jun 2025 | 0 | — | -2,548,045 | -2,360,286 | 9,676,909 | 6,985,858 | 2,441,204 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,892,948
Investing CF
$-176,776
Financing CF
$2,809
CapEx
$-196,475
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.05
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-23,474,939
Inventory
—
Receivables
$302,863
ST Investments
—
EBIT TTM
$-10,152,717
Pretax Income TTM
$-9,777,765
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,716,471 | -9,158,734 | 5,971,517 | 2,574,268 | — | -6,502,040 |
| Dec 2024 | 0 | -5,932,105 | -5,861,335 | 13,034,404 | 2,613,629 | — | -8,505,650 |
| Dec 2023 | 0 | -1,796,222 | -2,038,389 | 3,558,509 | 3,942,828 | — | -1,180,870 |
| Dec 2022 | 0 | -1,332,667 | -1,396,128 | 2,685,658 | 1,313,126 | — | -1,257,096 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MGX | Metagenomi Therapeutics, Inc. | $44.80M | $1.19 | — |
| TCRX | TScan Therapeutics, Inc. | $45.38M | $0.74 | — |
| INMB | Inmune Bio, Inc. | $46.52M | $1.75 | — |
| SCLX | Scilex Holding Co | $46.87M | $6.66 | — |
| ATYR | aTYR PHARMA INC | $47.65M | $0.49 | — |
News headlines (Yahoo Finance, 1h cache)
eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
2026-07-23 20:15 · Yahoo
Q2 Virtual Investor Summit Presentations Now Available On Demand
2026-06-30 17:20 · Yahoo
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
2026-06-24 20:10 · Yahoo
Q2 Investor Summit Virtual Live Wednesday June 24
2026-06-23 19:40 · Yahoo
eXoZymes Inc. Announces Closing of $6 Million Public Offering
2026-06-17 20:10 · Yahoo
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
2026-06-08 13:00 · Yahoo
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
2026-05-07 13:05 · Yahoo
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
2026-04-10 13:10 · Yahoo
MDB Capital Holdings LLC (MDBH) Q4 2025 Earnings Call Highlights: Strategic Innovations and ...
2026-04-07 01:00 · Yahoo
EXoZymes Inc (EXOZ) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
2026-04-01 03:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.